dawn kleindorfer, md associate professor august 27 th, 2008
Post on 13-Jan-2016
217 Views
Preview:
TRANSCRIPT
Dawn Kleindorfer, MD
Associate Professor
August 27th, 2008
Financial Disclosures Site Principal Investigator, PRoFESS
study, 2004-2008
Speaker’s Bureau, Boehringer IngelheimNon-significant category, per UC guidelines
Member, National Stroke Experts Advisory Panel, Boehringer Ingelheim, 8/08
Discussion Cases
65yo BF, with HTN, presents with her first ischemic stroke, small vessel subtype.Which antiplatelet at discharge?
72yo WM c HTN, DM, HLD, smoking, presents with his second ischemic stroke, R MCA infarct, on aspirinWhich antiplatelet at discharge?
Bottom Line for Stroke Prevention? Still will be controversial as to which anti-
platelet is first line
PRoFESS showed that aggrenox and plavix are equally effective and both are options
Previous data had shown aggrenox is better than aspirin, and more controversially, that plavix is better than aspirin, PRoFESS doesn’t change that
Bottom Line?
Issues such as patient compliance, financial situation, history of headaches, may need to be factored in for each patient
Don’t forget other risk factors! May make a much larger impact than agonizing over antiplatelets….
top related